Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$29.31 USD

29.31
242,085

+0.02 (0.07%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $29.55 +0.24 (0.82%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View

by Zacks Equity Research

Omnicell (OMCL) aims at product innovation through R&D.

Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 4.69% and 1.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Omnicell (OMCL) Catches Eye: Stock Jumps 8.2%

by Zacks Equity Research

Omnicell (OMCL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Here's Why You Should Invest in Omnicell (OMCL) Stock Now

by Zacks Equity Research

Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.

Sweta Killa headshot

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa

Sector ETF report for PSCH

Why Is Omnicell (OMCL) Up 4.8% Since Last Earnings Report?

by Zacks Equity Research

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Will Omnicell (OMCL) Gain on Rising Earnings Estimates?

by Zacks Equity Research

Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Sweta Killa headshot

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa

Sector ETF report for PSCH

NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NXGN vs. OMCL: Which Stock Is the Better Value Option?

Omnicell (OMCL) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Omnicell (OMCL) gains from solid segmental contributions in Q1; margins expand.

Omnicell (OMCL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

by Zacks Equity Research

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell's Global Expansion on Track, Stiff Competition Ails

by Zacks Equity Research

Although Omnicell (OMCL) is steadily expanding in the Middle East and South African belts, it sees a greater uptake of technologies across other regions of the world.

Omnicell (OMCL) Up 27.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.

Omnicell (OMCL) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 4.48% and -1.35%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Omnicell Solid on Geographic Expansion Amid Stiff Competition

by Zacks Equity Research

Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.

Omnicell (OMCL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark

by Zacks Equity Research

Illumina's (ILMN) Q4 figures show a sturdy uptick in sequencing consumable revenues.

Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

by Zacks Equity Research

We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.

Thermo Fisher (TMO) Down on Business Divestment Declaration

by Zacks Equity Research

Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.

CVS Health's PBM Pharmacy Platform to Ride on Walmart Deal

by Zacks Equity Research

Per the terms of the deal between CVS Health (CVS) and Walmart, the latter will continue to take part in the CVS Caremark PBM commercial and Managed Medicaid retail pharmacy networks.

Neogen Gains on Strong Genomic Arm Amid Stiff Competition

by Zacks Equity Research

Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.

Why You Should Consider Buying Omnicell (OMCL) Stock Now

by Zacks Equity Research

Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.